Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALMB-0166 in acute spinal cord injury
NCT05524103Phase 1Completed
- Sponsor
- AlaMab Therapeutics
- Start
- Apr 2022
- Primary completion
- Feb 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in spinal cord injury (SCI) comparing ALMB-0166 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 2 months. Started Apr 2022; status: completed.
02
Drugs
ALMB-0166
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT05524103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524103.